APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 0.1-1 μg/ml |
| 1:250 |
Not tested in other applications.
Calculated MW
Product Note
This antibody is raised against human c-Abl (isoform b) phosphorylated at Tyr245. Based on sequence homology, it is predicted to react with c-Abl (isoform a) and ABL2 when phosphorylated at the corresponding residues - c-Abl (isoform a) Tyr226 or ABL2 Tyr272.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.05% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
synthesized phosphopeptide derived from a region of human c-Abl that contains tyrosine 245
Purification
Purified IgG
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
ABL proto-oncogene 1, non-receptor tyrosine kinase , ABL , CHDSKM , JTK7 , bcr/abl , c-ABL , c-ABL1 , p150 , v-abl
Cellular Localization
Cytoplasm, cytoskeleton,Nucleus,Mitochondrion
Background
This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014]
Database
Research Area
DATA IMAGES
|
GTX24479 ICC/IF Image
ICC/IF analysis of HeLa cells treated with 4 uM Curcumin for 4hr using GTX24479 c-Abl (phospho Tyr245) antibody. Panel e shows the untreated cells with nuclear localization. Panel e shows the no primary antibody control.
Green : Primary antibody
Blue : Nuclei
Red : Actin
Fixation : 4% paraformaldehyde
Permeabilization : 0.1% Triton X-100 for 10 minutes
|
|
|
GTX24479 WB Image
WB (peptide competition) analysis of fibroblasts transfected with oncogenic DSH3-Abl using GTX24479 c-Abl (phospho Tyr245) antibody with the non-phosphopeptide corresponding to the phosphopeptide immunogen (Lane 2), a generic phosphothreonine-containing peptide (Lane 3), or the phosphopeptide immunogen (Lane 4) control. The data show that only the immunogen phosphopeptide blocks the signal, demonstrating the specificity of the antibody.
|
REFERENCE
There are currently no references for c-Abl (phospho Tyr245) antibody (GTX24479). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for c-Abl (phospho Tyr245) antibody (GTX24479). Be the first to share your experience with this product.
